PneumoWave Achieves 510(k) Clearance For Data Collection Product
[Glasgow, Scotland – Tuesday, 6th May, 2025] We’re pleased to share that PneumoWave has received Class II FDA 510(k) clearance for our Data Collection Mobile
May 6, 2025
[Glasgow, Scotland – Tuesday, 6th May, 2025] We’re pleased to share that PneumoWave has received Class II FDA 510(k) clearance for our Data Collection Mobile
[Glasgow, Scotland – Thursday 31st October, 2024] https://www.gov.uk/government/news/virtual-reality-and-wearable-technology-pilot-to-cut-drug-deaths Government awards £12 million to research projects across the UK that are researching innovative technology to support
[Glasgow, Scotland – Monday 23rd September, 2024] https://www.researchprotocols.org/2024/1/e57367 A joint paper was published in JMIR Research Protocols, vol 13 (2024), detailing the OD-SEEN (Overdose Sensor
PneumoWave, an innovator in the fight against the opioidepidemic, is proud to announce that it has achieved ISO 13485:2016 certification and has registered aversion of its technology as a Class 1 UKCA device.
UK-based startup PneumoWave devises a chest-worn smart biosensor. The biosensor captures respiratory data and the startup’s platform analyses it using machine learning algorithms
PneumoWave, an innovator in the fight against the opioid epidemic with operations in Scotland and the U.S., proudly announces the appointment of Nicola Broughton as its new Non-Executive Director.
PneumoWave, a digital therapeutics company based in Scotland and the U.S., has announced the appointment of digital medicine and MedTech pioneer Richie Bavasso as the new President of the organization and member of the Board of Directors.
PneumoWave today announced the closing of £7.5 m Series A financing which will enable clinical validation and regulatory submission of its biosensor technology platform
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
Altair Medical, a medical technology company developing a groundbreaking solution to the global opioid crisis, today announce that the US Food and Drug Administration (FDA) has awarded the Company Breakthrough Device designation for its wearable biosensor device.